Benzodiazepine and barbiturate ligands modulate responses of cultured hippocampal neurones to the GABAA receptor partial agonist, 4-PIOL.
We have previously characterized 5-(4-piperidyl)isoxazol-3-ol (4-PIOL) as a non-desensitizing partial agonist at GABAA receptors and shown that the responses are mediated by short-duration channel openings consonant with single-ligand gated openings of the Cl- channels. We presently investigate whether responses of cultured rat hippocampal neurones to 4-PIOL are modulated by benzodiazepine (BDZ) and barbiturate receptor ligands. Whole-cell patch-clamp recordings of maximal responses to 1 mM 4-PIOL were comparable in size to responses evoked by 10 microM of the full GABAA agonist, isoguvacine. The BDZ receptor inverse agonist, DMCM (1 microM) reduced responses to isoguvacine (to 65.7 +/- 11.0%) and 4-PIOL (to 69.3 +/- 3.5%) to a similar extent. The BDZ agonist, midazolam (0.1 microM) potentiated responses to both agonists, and resulted in responses with an early peak with later fading. Potentiation of the peak response to 4-PIOL (to 163 +/- 14%) was significantly less than for isoguvacine (215 +/- 11%). Pentobarbital (50 microM) caused a very marked, but variable, potentiation of the peak response to 4-PIOL (to 484 +/- 93%), which was significantly greater than the potentiation of the peak response to isoguvacine (to 304 +/- 46%), and induced fading. This suggests that a relatively larger number of the 4-PIOL-induced channel openings can be transformed to longer duration openings by pentobarbital. In conclusion, responses to 4-PIOL and isoguvacine are modulated by BDZ and barbiturate ligands in a qualitatively similar manner, but with a number of quantitative differences which cannot be readily explained by the kinetic model of Macdonald and Twyman (1992). Investigation of these responses at the single-channel level could provide further insight into the operation of the GABAA receptor-ionophore complex.
Kristiansen
U
U
Department of Biology, Royal Danish School of Pharmacy, Copenhagen, Denmark.
Lambert
J D
JD
D000818:Animals; D001463:Barbiturates / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology*; D002243:Carbolines / Q000494:pharmacology; D002478:Cells, Cultured; D003292:Convulsants / Q000494:pharmacology*; D004594:Electrophysiology; D018755:GABA Agonists / Q000494:pharmacology*; D018757:GABA Modulators / Q000494:pharmacology*; D058785:GABA-A Receptor Agonists; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007539:Isonicotinic Acids / Q000494:pharmacology; D007555:Isoxazoles / Q000494:pharmacology*; D008564:Membrane Potentials / Q000187:drug effects; D008874:Midazolam / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D010424:Pentobarbital / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats
D001463:Barbiturates; D002243:Carbolines; D003292:Convulsants; D018755:GABA Agonists; D018757:GABA Modulators; D058785:GABA-A Receptor Agonists; D006993:Hypnotics and Sedatives; D007539:Isonicotinic Acids; D007555:Isoxazoles; D010880:Piperidines; D001569:Benzodiazepines; C034818:methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate; C073009:5-(4-piperidyl)isoxazol-3-ol; D010424:Pentobarbital; D008874:Midazolam; C015300:isoguvacine